98%
921
2 minutes
20
In this study, high performance liquid chromatography (HPLC) and second derivative spectrophotometry have been used and described for the simultaneous determination of montelukast and loratadine in pharmaceutical formulations. HPLC separation was achieved with a Symmetry C18 column and sodium phosphate buffer (pH adjusted to 3.7): acetonitrile (20:80, v/v) as eluent, at a flow rate of 1.0 ml/min. UV detection was performed at 225 nm. The LC method is simple, rapid, selective and stability indicating for the determination of montelukast. 5-Methyl 2-nitrophenol was used as internal standard for the purpose of quantification of both the drugs in HPLC. In the second-order derivative spectrophotometry, for the determination of loratadine the zero-crossing technique was applied at 276.1 nm, but for montelukast peak amplitude at 359.7 nm (tangent method) was used. Both methods were fully validated and a comparison was made for assay determination of selected drugs in formulations. The results confirm that the methods are highly suitable for its intended purpose.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0731-7085(02)00650-7 | DOI Listing |
J Med Life
July 2025
Department of Dermatology and Allergology, Elias Emergency University Hospital, Bucharest, Romania.
Systemic mastocytosis (SM) is a rare clonal mast cell disease characterized by heterogeneous clinical presentations and molecular features that vary across different regions; however, data from Central-Eastern Europe remain limited. This study aimed to describe the demographic, clinical, laboratory, and molecular characteristics of Romanian adults diagnosed with SM and followed at the national reference center for mast cell disorders in Bucharest, while also exploring real-world management patterns and outcomes. We conducted a retrospective observational study including 162 adult patients evaluated between January 2006 and March 2025 who met the 2022 World Health Organization criteria for SM.
View Article and Find Full Text PDFJ Affect Disord
December 2025
Department of Pharmacy, Tongling People(')s Hospital, Bijiashan Road, Tongguan District, Tongling, Anhui province 244000, China. Electronic address:
Objective: This study aims to use the Food and Drug Administration Adverse Event Reporting System (FAERS) to identify medications linked to memory disorders and to offer updated insights into medication-induced memory disorders.
Methods: We analyzed adverse event (AE) reports related to memory disorders in the FAERS database from 2004 to 2023 and compiled a list of potential medications along with their associated AEs. The disproportionality analysis was employed to assess the potential associations between medications and memory disorder events.
J Asthma
August 2025
Departamento de Farmacología y Toxicología, Facultad de Medicina, Grupo de Investigación en Farmacología y Toxicología. Universidad de Antioquia, Medellín, Colombia.
Introduction: The treatment of cough variant asthma is the same as for asthma in general. Recent evidence suggests montelukast (Mon) + fluticasone propionate (Flu) reduced cough recurrence regarding Flu in monotherapy. For health insurers whether this extra benefit offered by this combination of Flu is compensated by this additional cost compared to monotherapy with Flu.
View Article and Find Full Text PDFNew Microbes New Infect
August 2025
ASST Spedali Civili di Brescia. SC Malattie Infettive, 25123 Brescia, Italy.
This systematic review investigates experimental and repurposed antiviral molecules for epidemic-potential arboviruses, including dengue (DENV), Zika (ZIKV), chikungunya (CHIKV), West Nile (WNV), and Usutu (USUV) viruses. Arboviral diseases pose a growing public health concern, exacerbated by climate change and increased global travel. Despite the absence of approved antiviral therapies for most arboviruses, numerous , and in human studies have evaluated candidate molecules targeting the different stages of viral replication.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
July 2025
Department of Research and Evaluation, KPSC, Pasadena, CA, USA.
Background: Knowledge of risk factors in early childhood predisposing to moderate-severe persistent asthma (MS-Asthma) in later childhood are needed.
Objective: To identify the risk factors for MS-Asthma at 5-11 years in children with early-onset atopic dermatitis (AD).
Methods: Electronic health records identified a birth cohort to 11 years of 10,688 children with AD onset between birth and age 36 months.